SK Life Science, Inc.
Clinical trials sponsored by SK Life Science, Inc., explained in plain language.
US subsidiary of SK Biopharmaceuticals, developing CNS drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with focal seizures: cenobamate trial underway Results expected Nov 2026 (estimated)
- New epilepsy drug tested as standalone treatment Results expected May 2027 (estimated)
-
New epilepsy drug candidate aims to tame severe seizures
Disease control CompletedThis study tests whether cenobamate, an experimental anti-epileptic drug, can safely reduce primary generalized tonic-clonic (PGTC) seizures when added to a person's usual seizure medications. Adults and adolescents aged 12 and older with PGTC seizures are randomly assigned to re…
Phase 3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New epilepsy drug shows promise for Long-Term seizure control
Disease control CompletedThis study looked at the long-term safety of the drug cenobamate when added to existing treatment for people with primary generalized tonic-clonic seizures. A total of 147 participants who completed an earlier study took cenobamate for up to 52 weeks. Researchers tracked side eff…
Phase 3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New seizure drug shows promise in large trial
Disease control CompletedThis study tested a drug called cenobamate in 519 adults with partial onset seizures (focal seizures). Participants took cenobamate or a placebo alongside their usual seizure medications. The goal was to see if cenobamate could safely reduce seizure frequency. Results showed a si…
Phase 3 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New epilepsy drug tested in kids for first time
Knowledge-focused CompletedThis study tested a medicine called cenobamate in 26 children with partial-onset seizures. The goal was to see how the drug moves through the body and if it is safe. The study did not aim to cure or control seizures long-term, but to gather important information for future use.
Phase 1 • Sponsor: SK Life Science, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC